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The Vif (viral infectivity factor) protein of HIV-1 enhances viral infectivity during virus 
production 100 to 1000 fold (4). Though Vif is required for HIV-1 infection in peripheral blood T 
lymphocytes, macrophages, and some T cell lines, its exact role during HIV-1 infection remains unknown 
(13). Currently, it is proposed that Vif may affect the late phases of the viral life cycle, such as virion 
assembly and maturation (4). In order to get a better understanding of the function and mechanism of Vif, 
obtaining the structure of the protein is of extreme importance. Unfortunately, no structural information is 
available. Determining the structure of a protein using NMR (nuclear magnetic resonance) spectroscopy 
requires that the protein be monomeric in solution. However, Vif exists in solution as aggregates, making 
NMR impossible. Constructing deletion mutants of Vif may change the protein’s aggregation behavior to 
monomeric in solution. Thus, these mutants may be the key to determining the structure of Vif, which, in 
turn, may lead to a better understanding of its function and indicate possible HIV-1 drug targets. PCR 
(polymerase chain reaction) was used to make the Vif deletion mutants. Restriction digests were 
performed on both the vector (pDlOVif) and the PCR product using the enzymes BamHl and Hindlll. A 
ligation and transformation were performed, and transformants were selected for using Ampicillin 
resistance. A plasmid prep was performed and another restriction digest was performed and run on an 
agarose gel to ensure the presence of the insert. The Vif mutant was then sequenced as an extra precaution 
before performing a protein expression test to determine whether or not the protein was soluble.
INTRODUCTION
Background
HIV has a spherical shape, with a diameter of 1/10,000-mm (10). Its outer coat is called the viral 
envelope, and is made of a lipid bilayer. Protruding from the envelope surface is the Env protein, with a 
cap made from 3 or 4 gp 120 molecules and a stem made from 3 or 4 gp41 molecules. Made of 2000 
copies of the protein p24, the capsid surrounds two single strands of HIV RNA within the envelope (10).
Like any retrovirus, HIV contains the genes Gag, Pol, and Env. The Gag gene is translated into 
the molecules that make up the capsid protein, while the Env gene is translated into the molecules of the
envelope protein. The Pol gene is transcribed into the molecules of reverse transcriptase, protease, and 
integrase (7). However, early into the infective process, Gag, Pol and Env are not made. Instead, RNA is 
first processed, creating six auxiliary proteins, each contributing to some aspect of the HIV-1 life cycle, 
which is briefly explained below.
CD-4 Receptors on the host cell bind to the viral envelope protein, the envelope fuses with the cell 
membrane, and the viral capsid is taken into the cell. When the capsid opens, the viral RNA, 
reverse transcriptase, and tRNA primers are released into the host cell. A double-stranded DNA 
copy of the RNA is synthesized by the reverse transcriptase, and the DNA copy is integrated into 
the host cell genome, where it is then called a provirus. This provirus DNA is then transcribed 
into RNA to produce viral proteins, and the new virus particles are assembled and released from 
the cell by budding off (9).
The first of these auxiliary proteins is Tat (transcriptional activation protein). Tat is responsible for 
activating the transcription of the HIV-1 LTR (long-terminal repeat) promoter, and it is also necessary for 
viral replication (3). The Rev protein is responsible for the nuclear export of late HIV-1 mRNA (3). Nef 
(numerous effector functions) was once thought to be a negative elongation factor, but instead plays a role 
in the down-regulation of cell surface CD-4 and MHC-1. As a result, complexes formed between CD-4 
and the HIV-1 envelope would be reduced, and cytotoxic T lymphocyte mediated lysis of infected cells 
would be inhibited (3). Nef is also thought to enhance virion activity. The protein Vpr mediates the import 
of HIV-1 preintegration complexes into the nucleus of non-dividing cells. It also arrests the cell in the G2 
phase of the cell cycle, so that mitosis cannot occur (3). Unique to HIV-1, Vpu enhances the release of 
virions from infected cells and the selective degradation of CD-4 in a cell’s endoplasmic reticulum (3).
The least understood of these auxiliary proteins is Vif. A singly spliced mRNA that is dependent on Rev 
encodes this 192 amino acid protein (3).
Significance of Vif
Many ideas as to the role of Vif have been put forth, and will be discussed further on. Knowing 
the structure of Vif may tell a lot about its function and mechanism, and may lead to new and more 
successful drug therapies.
One of the reasons that the role of the 23 kDa Vif protein is so poorly understood is that only 
certain cells require Vif for efficient HIV-1 replication (13). The cells that require Vif for replication are 
termed nonperm issive, while cells that do not require Vif for replication are termed permissive (12). The 
fact that some cells require Vif and others do not suggests that Vif can somehow compensate for cellular
factors needed for production of infectious virus particles in some cell lines (permissive) but are absent in 
others (nonpermissive) (4).
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Previous studies show that Vif deficient (Vif) mutants recovered from nonpermissive cells have 
abnormal features, such as reduced quantities of envelope protein and altered quantities of the Gag and Pol 
proteins (1). Furthermore, a V if virus produced in a nonpermissive cell cannot replicate in the target cell, 
but a V if virus produced in a permissive cell can (1). Borman et al. transfected HeLa cells to generate both 
wild type and V if viruses, which were used to infect different transformed T cell lines (1). The V if 
mutants from nonpermissive cells were 25-100 times less infectious than wild type Vif (1). After one 
round of V if mutant infection in nonpermissive cells, normal quantities of virus were released, but were 
noninfectious (1).
Evidence shows that Vif affects late events in the virus life cycle, such as virion assembly, 
budding, or maturation (12). Double-label immunofluorescence analyses of HIV-1 infected cell, performed 
by Simon et a l . , indicate that the Vif and Gag proteins colocalize at the plasma membrane as virion 
assembly and budding occur, thereby allowing Vif to mediate these steps in the virus life cycle (12). 
Mutagenesis studies by Goncalves et al. show that basic domains in V if s C terminus are necessary for 
membrane association (5). Disrupting this membrane association also inhibits HIV-1 replication. Thus, the 
membrane localization o f Vif may be critical to its biological activity (5).
In another study, Yang et al. found that Vif is phosphorylated and regulated by p44/42 mitogen- 
activated protein kinase (MAPK) on Ser165 and T hr96 residues (14). Mutations in the Thr96 site, as well as 
other phosphorylation sites not regulated by MAPK, resulted in the loss of Vif activity and inhibition of 
HIV-1 replication (14). These findings indicate that the phosphorylation may induce a conformational 
change necessary for its biological activity, mediate its membrane association, or promote its interaction 
with the Gag protein, all affecting the assembly of the virus (14). The study also indicates that without Vif, 
virions can begin reverse transcription, but cannot complete it (14).
Similarly, the study by Borman et al. also notes that V if mutants are incapable of DNA synthesis 
in target cells, suggesting that reverse transcription is initiated, but is inefficient (1). A paper by Bryan 
Cullen further supports the notion that reverse transcription fails to go to completion, although the exact 
stage at which failure occurs is debated (3). After reaching the nucleus, little or no full-length provirus is
produced, and the partial transcripts are degraded (3). Thus, Vif is needed for the prolonged accumulation 
of reverse transcripts in HIV-1 infected cells, and its absence allows for their degradation (13).
Another report showed that Vif might act to inhibit HIV-1 protease, thereby preventing premature 
cleavage of certain structural proteins (8).
With all the speculation as to exactly what V if s role is, structural information may be able to give 
researchers a clue to V if s function. Since Vif exists as aggregates in solution, structural studies using 
NMR are not feasible. The protein must be monomeric in solution. Past studies have shown that making 
mutations in a protein can change its aggregation behavior (6). Hence, deletion mutants may be the key to 
determining the structure of Vif.
Materials and Methods
The bacterial expression plasmid pDlOVif, obtained from Dana Gabuzda of Harvard University, 
has the full-length wild type Vif gene fused with an N-terminal 6-His tag. PD1 OVif was used to express 
the mutant proteins created. The PCR primers contained non-homologous 5’ regions that encode the 
restriction enzyme sites Bam-Hl and Hind III (see Results). These sites match those on pDlOVif, allowing 
for easy insertion of the mutant gene into the vector, which was then transformed into bacterial cells to 
express protein.
PCR: lpl of template (200ng/pl), .8pl of dNTP’s, 1.5pl o f primer 1, 1.5pl of primer 2, lOpl of 
10X buffer and 82.5jil of sterile water were pipetted into an eppendorf tube, and put in the thermal cycler. 
After window 1 of PCR, the tube was microfuged, .5 pi of taq polymerase was added, and the tube was 
microftiged again and put back into the thermal cycler until PCR was complete.
To ensure that the PCR product was there, a 2% agarose gel was run. The gel was made from 
60ml of 10X TAE, .72g o f agarose, and 3pl of Ethidium Bromide. Note: all 2% agarose electrophoresis 
gels were run for 30 minutes at 100 volts.
Restriction Digests: Restriction digests were performed on both the PCR product, and the 
pDlOVif vector. For the first digest, 40pl of PCR product, 5pl o f 10X buffer E, lpl of BSA, 2pl of Bam- 
H l, and 2pl of Hind III were added to the tube for a total volume of 50pl. For the second digest, 3pl of the
pDlOVif vector, lpl of BSA, 5pl of 10X buffer E, 37pl of water, 2pl Bam-Hl, and 2jnl of Hind III were 
added to the tube for a total volume of 50pl. Both tubes were put in a hot water bath at 37°C for 3 hours.
Another 2% agarose gel was run to make sure that the vector was cut. The digested vector was 
compared to the uncut vector.
Dephosphorylation of 5’ ends using CIAP: lOpl of 10X CIAP (calf intestinal alkaline 
phosphatase) reaction buffer, 2pl of CIAP, 63 pi of water, and 25pl of the digested vector were added to a 
tube and incubated for 30 minutes at 37°C. Then lpl more of CIAP was added, and the tube was incubated 
for an additional 30 minutes at 37°C. 2pl of .5M EDTA was added to stop the reaction, and the tube was 
heated at 65°C for 20 minutes.
The vector was purified using the Promega Wizard® Plus Minipreps DNA Purification System 
protocol. The purified vector was then run on another 2% agarose electrophoresis gel. The vector 
restriction digest with CIAP treatment had to be repurified with the Promega Wizard® Plus Minipreps 
DNA Purification System. The PCR product was also purified using the Promega PCR Miniprep protocol. 
A 2% agarose gel was run.
Another restriction digest was performed on the vector, as previously explained, a 2% agarose gel 
was run, and the DNA was cut from the gel and placed in a 1.5ml tube so that gel purification could be 
performed. 1ml of Wizard® Minipreps DNA Purification Resin was added to the tube with the gel and 
incubated at 65° for 5minutes, until the gel had melted. Purification using the vacuum manifold was 
performed as indicated by Promega protocol. Another 2% agarose gel was run to see if the vector was 
present.
Ligation: Ligation reactions were performed using 2 different purified vectors. The control 
contained 4pl of vector, 1 pi of Buffer, 1 pi of Ligase, and 4pl of water. The purified vector prepared by 
Sanna Hakansson was split into two different tubes. One contained lp l vector and 7pl of PCR (SV1), 
while the other contained 3pl o f vector and 5pl of PCR (SV2). Both reactions contained lpl of Buffer and 
1 pi of Ligase. The other purified vector, prepared by myself, was prepared the same way as described 
above (CV1 and CV2, respectively).
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Transformation: Plates were already prepared containing LB agar and Ampicillin. Frozen 
JM109 Competent Cells were removed from -70°C and placed on ice until thawed. 1 Opl of ligated cells 
were added to the JM109 cells and placed on ice for 30 minutes. The cells were heat-shocked in a hot 
water bath for 45-50 seconds at 42°C and placed on ice for 2 minutes. 900pl of room temperature SOC 
medium was added to each transformation reaction and incubated for 60 minutes at 37°C with shaking. For 
each tube, lOOpl of cells were plated and incubated at 37°C for 12-14 hours.
20pl of Ampicillin were added to each of two flasks containing 20ml of LB agar. The flask were 
inoculated with colonies from plates SV1 and CV2 and allowed to shake over night at 37°C. These cells 
were then purified using the Promega Wizard® Plus Minipreps DNA Purification System for 5-10ml of 
bacterial culture.
A restriction digest was performed using 5pl of DNA, 2pl of Bam-Hl, 2pl of Hind III, 2jil of 
BSA, 2pl o f Buffer E, and 7pl of water. A 2% agarose gel was run first using dye, and then without using 
dye.
Two flasks were re-inoculated using colonies from plates SV2 and SV1, as previously described. 
The plasmid prep was performed using the Promega Wizard® Plus Minipreps DNA Purification System 
protocol. Restriction digests were performed on SV2 and SV3 as previously described, and a 2% agarose 
gel was run to see if the insert was present.
The plasmid prep SV3 was prepared for sequencing. The sample was dried in the speed vac, and 
20ul of water were added to dilute the sample to 250ng/ml. The sample was then sequenced by Scott 
Graybum in NIU’s DNA Synthesis and Sequencing Lab.
The pDlOVif vector was re-cut using the restriction digest protocol discussed previously. A 2% 
agarose gel was run, and gel purification was performed using the Promega purification procedure 
previously mentioned. Another ligation and transformation were performed. A colony from plate #1 was 
inoculated into a flask containing 20pl Ampicillin and 20ml of LB. The cells were purified using the 
Promega Wizard® Plus Minipreps DNA Purification System protocol for 5-10ml of bacterial culture. A 
restriction digest was performed and a 2% agarose gel was run.
RESULTS
The primers used for PCR both contain Bam-Hl and Hind III restriction sites. The sequence of 
primer #1 is 5’ GGCGG ATCC ATTCATCTGTATTACTTT 3’. The sequence of primer #2 is 
5’ GGGGAAGCTTCTAGTGTCCATTCAT 3’. The bolded segments represent the Bam-Hl and Hind III 
restriction sites, respectively. The underlined segments are where the sequences begin.
Vif is 192 amino acids long, but the mutant constructed contains a deletion of the first 106 amino 
acids. Thus, the Vif mutant starts at amino acid 107 and ends with amino acid 192. The sequence of the 
final, desired protein would contain methionine (ATG) as the start site, followed by the 6-His tag, the 
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Figure 1 shows the first 2% agarose gel run, and allows one to make sure that the desired product 
is present. Lane 1 contains the X DNA/EcoRl+Hind III molecular weight marker, while lane 2 contains the 
PCR product. The whited in band in lane 2 has a molecular weight of <1.375Kb, indicating that the desired 
product is present. (Note: the same X marker was used for each gel. Each band of the marker represents 
the molecular weights labeled in Fig.l)
Figure 2 shows the gel run after the first restriction digest. Lane 1 contains the X marker; lane 2 
contains the digested pDlOVif vector; and lane 3 contains the uncut plasmid, allowing for a comparison 
between the cut and uncut vector. Lane 2 indicates a clean cut. The cut plasmid ran slower (~10Kb) 
compared to the supercoiled, uncut plasmid in lane 3 (~7Kb). A second band is also present in lane 2 at 
~1.375Kb.
Figure 3 shows the gel run after CIAP treatment and vector purification, in order to obtain the 
concentration of the purified vector. Lane 1 contains a dilution of the X marker; lane 2 contains the vector; 
lane 3 contains the un-diluted X marker; lane 4 contains the digested PCR product; and lane 5 contains a
ladder marker. Although not visible in this figure, the original photograph showed the ladder marker in 
lane 5, as well as the PCR digest in lane 4 (<1.375Kb). However, the vector in lane 2 was not present, 
calling for a re-purification of the vector. The PCR digest was purified as well. Another gel was run, and 
again the vector was lost.
Because the vector was not showing up on the gels, another restriction digest was performed. This 
digested vector was run on a gel, and an alternative purification method was used—gel purification—where 
the band is cut out of the gel. However, this method was also unsuccessful, as the vector was once again 
lost when run on a gel.
Although the vector was not visible, it may have still been present. Perhaps the concentration was 
not high enough to see on a gel. Hence, a ligation and transformation were performed. Two different 
vectors were used in two different ligations. One was purified by Sanna Hakansson (SV1 and SV2), and 
the other was purified by myself (CV1 and CV2). Different amounts of vector and PCR product were put 
into four different tubes—SV1, SV2, CV1, and CV2. The ligated vector and insert were transformed into 
'Vs* ^ / JM109 cells. Plates SV1 and CV2 showed growth and were used to inoculate flasks containing LB and
Ampicillin. Only flask SV1 showed growth after shaking over night at 37°C. The DNA was purified, and 
a gel was run. The Bam-Hl/Hind III fragment was not seen at the right size, which is ~300 bases. Another 
gel was run without dye to see if a band could be distinguished at 300 bases. Again, no band was visible on 
the gel. Flasks were re-inoculated using colonies from plates SV1 and SV2. A purification was performed, 
restriction digests were done, and another gel was run (Figure 4). Lane 1 in figure 4 contains the X marker; 
lane 2 contains 5|nl of the digest SV1; lane 3 contains 5 pi of the digest SV2. No bands were visible, so 
15pl of the digests were loaded onto the same gel. Lane 4 contains the X marker; lane 5 contains the digest 
SV1; lane 6 contains the digest SV2. As indicated by the whited in band in Fig.4, the insert was seen at 
300 bases.
Figure 5 is an electroferrogram showing the sequence obtained from NIU’s DNA Synthesis and 
Sequencing Lab. Unfortunately, it appears as though the PCR products and vector self-ligated. The 
pDlOVif vector was re-cut, a gel was run, and a gel purification was performed. Another ligation and
transformation were performed. Plate #1 showed growth and was inoculated into a flask containing LB and 
Ampicillin. The cells were purified, a restriction digest was performed, and a gel was run. Again, the 
vector was not visible.
CONCLUSION
Though the experiments did not work, I learned a lot about lab technique and research methods. I 
also learned to work with other people to troubleshoot to try to figure out where something may have gone 
wrong, and how sterile technique plays a large role in the success o f an experiment.
I still believe that further research should be conducted concerning Vif. Making deletion mutants 
is vitally important to making Vif monomeric in solution, and ultimately allowing for a structure to be 
obtained using NMR spectroscopy. Determining the structure of Vif could give clues as to what Vif does, 
and how it does it. This could lead to new and better drug therapies.
Since HIV can integrate into the host’s genome and undergo a period of latency, it is important to 
find ways to delay the symptoms and keep the virus from proliferating. The HIV life cycle contains more 
than a dozen steps. Thus, interrupting any one of these steps could prevent the virus’ detrimental affects 
(2).
For example, AZT works to stop the reverse transcription of RNA into DNA, which would then 
integrate into the host cell’s genome (2). Various protease inhibitors stop protease from cutting the proteins 
before a new virus can assemble. The problem with these drugs has been that the virus mutates into a strain 
that is resistant to the drug (2). The HAART drug combines both protease and reverse transcriptase 
inhibitors, which significantly decreases the viral load since the virus must overcome 2 barriers instead of 
just one in order to become resistant. If V if s mechanism is found, a drug could be designed to prevent Vif 
from functioning properly, and consequently, prolong many lives.
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